Blood tests for circulating tumor DNA raise questions

The blood tests can suggest when cancer is likely to recur. But for now, nobody knows exactly what to do with that information.

June 18, 2024 Check out STAT+

Sponsored By

Adobe STAT+ | Oncologists turn to blood test for circulating tumor DNA, but questions remain on how to use the data The tests for ctDNA are seen as good indicator of whether cancer will return after surgery. But they don't always clarify the next step. By Angus Chen Vaping is just as good as Chantix at helping people quit cigarettes, new study finds E-cigarettes were nearly as effective at helping people quit smoking as the gold-standard pharmaceutical drug varenicline, JAMA study says. By Nicholas Florko STAT+ | Will Geron be acquired? The long-short view This week in biotechnology: Adam Feuerstein's subscriber-only newsletter digs into Geron and Candel Therapeutics. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser